Protagonist Therapeutics Inc (PTGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.94 Million) by net assets ($645.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Protagonist Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Protagonist Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Protagonist Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Protagonist Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Protagonist Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protagonist Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guanghui Energy Co Ltd
SHG:600256
|
0.064x |
|
MINTH GRP LTD UNSP.ADR/20
F:M3I0
|
N/A |
|
Pegasystems Inc
NASDAQ:PEGA
|
0.301x |
|
Sai Gon Thuong Tin Commercial Joint Stock Bank
VN:STB
|
-0.952x |
|
OHB SE
XETRA:OHB
|
-0.052x |
|
Exchange Income Corporation
TO:EIF
|
0.112x |
|
Rail Vikas Nigam Limited
NSE:RVNL
|
-0.131x |
|
UNIQA Insurance Group AG
VI:UQA
|
0.072x |
Annual Cash Flow Conversion Efficiency for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Protagonist Therapeutics Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Protagonist Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $675.29 Million | $184.15 Million | 0.273x | +230.72% |
| 2023-12-31 | $336.68 Million | $-70.24 Million | -0.209x | +58.41% |
| 2022-12-31 | $215.61 Million | $-108.14 Million | -0.502x | -39.50% |
| 2021-12-31 | $300.02 Million | $-107.86 Million | -0.360x | -38.69% |
| 2020-12-31 | $279.61 Million | $-72.48 Million | -0.259x | +50.08% |
| 2019-12-31 | $79.96 Million | $-41.53 Million | -0.519x | -16.99% |
| 2018-12-31 | $112.52 Million | $-49.95 Million | -0.444x | -1483.01% |
| 2017-12-31 | $120.63 Million | $3.87 Million | 0.032x | +109.38% |
| 2016-12-31 | $87.56 Million | $-29.97 Million | -0.342x | +77.16% |
| 2015-12-31 | $9.60 Million | $-14.38 Million | -1.499x | -54.01% |
| 2014-12-31 | $7.96 Million | $-7.74 Million | -0.973x | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more